also concluded that anti-TRIM21 can be a predictive marker for complication of ILD in patients with juvenile myositis, and also emphasized that it is likely to be associated with the severity of the disease, a worse prognosis, and an increase in the dosage of immunosuppressant medications during the follow-up period (172, 173). Here, TRIM21 is linked to interstitial lung disease.